This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Zoetis Stock Down Despite Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
ZTS stock falls despite better-than-expected fourth-quarter results due to a weak 2025 outlook.
ALNYPositive Net Change BMRNNegative Net Change ZTSPositive Net Change CSTLPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
HALO Gears Up to Report Q4 Earnings: Here's What You Should Know
by Zacks Equity Research
Halozyme's fourth-quarter earnings are likely to have gained from higher royalty payments and revenues from collaboration agreements for its Enhanze technology.
JNJPositive Net Change HALOPositive Net Change PCRXNegative Net Change MIRMNegative Net Change
biotechs
Alkermes' Q4 Earnings & Revenues Surpass Estimates, Stock Up
by Zacks Equity Research
ALKS reports better-than-expected fourth-quarter 2024 results. Net sales of proprietary products increase year over year. Shares rise.
ALKSNegative Net Change PCRXNegative Net Change HRMYNegative Net Change
biotechs earnings
EXEL Tops Q4 Earnings and Sales, Cabometyx Label Expansion in Focus
by Zacks Equity Research
Exelixis beats on Q4 earnings and sales as lead drug Cabometyx maintains momentum. The company reiterates its guidance for 2025.
ALNYPositive Net Change MRKPositive Net Change EXELNegative Net Change IMCRPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Biogen's Q4 Earnings & Sales Beat, 2025 EPS Guidance Disappoints
by Zacks Equity Research
BIIB's Q4 earnings and sales beat estimates. EPS guidance for 2025 falls short of expectations.
ALNYPositive Net Change BIIBNegative Net Change RHHBYPositive Net Change
biotechs
Sage Therapeutics' Q4 Earnings Miss Mark, Revenues Plunge Y/Y
by Zacks Equity Research
SAGE's earnings and revenues miss estimates in the fourth quarter of 2024. The company focuses on the commercialization of depression drug Zurzuvae.
BIIBNegative Net Change PCRXNegative Net Change HRMYNegative Net Change
biotechs earnings
CRISPR Therapeutics Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
CRSP reports encouraging fourth-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is progressing well.
ALNYPositive Net Change BMRNNegative Net Change VRTXNegative Net Change CRSPPositive Net Change
biotechnology biotechs crispr earnings gene-editing gene-therapy medical pharmaceuticals
GILD Stock Up on Q4 Earnings and Sales Beat & Upbeat '25 Guidance
by Zacks Equity Research
Gilead Sciences' Q4 earnings and sales beat estimates on higher HIV, oncology and liver disease drug sales. The stock is trading up.
GSKPositive Net Change ALNYPositive Net Change GILDNegative Net Change IMCRPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
BMY Down 7% Post Q4 Earnings: Should You Buy, Sell or Hold the Stock?
by Ekta Bagri
Bristol Myers' lackluster guidance for 2025 warrants caution. We recommend investors to wait and watch for the time being as generic competition for legacy drugs is a major headwind.
BMYNegative Net Change PFENegative Net Change MRKPositive Net Change
biotechnology biotechs earnings-report medical pharmaceuticals
VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales
by Zacks Equity Research
Vertex reports mixed fourth-quarter 2024 results as earnings miss estimates while revenues beat the same. Trikafta/Kaftrio drive year-over-year sales.
VRTXNegative Net Change CRSPPositive Net Change HRMYNegative Net Change
biotechs
Biogen Gears Up to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
In the fourth quarter, lower sales of BIIB's multiple sclerosis drugs and Spinraza are likely to have been offset by revenues from new drugs.
BIIBNegative Net Change MRNANegative Net Change NTLANegative Net Change
biotechs
Axsome Stock Surges 20% on Auvelity Patent Settlement With Teva
by Zacks Equity Research
AXSM stock rises 20% as it settles Auvelity patent litigation with Teva, protecting the drug's exclusivity in the United States at least until Sept. 30, 2038.
ALNYPositive Net Change BMRNNegative Net Change TEVAPositive Net Change AXSMNegative Net Change
biotechnology biotechs medical pharmaceuticals
Will These 5 Biotech Bigwig Stocks Surpass Q4 Earnings Forecast?
by Ekta Bagri
We focus on biotech stocks like VRTX, GILD, BIIB, ALNY and MRNA, which are scheduled to report this week.
ALNYPositive Net Change BIIBNegative Net Change GILDNegative Net Change VRTXNegative Net Change MRNANegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
INCY's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales
by Zacks Equity Research
Incyte reports mixed fourth-quarter 2024 results as earnings miss estimates while revenues beat the same. Jakafi and Opzelura drive year-over-year sales.
NVSPositive Net Change LLYPositive Net Change INCYPositive Net Change HRMYNegative Net Change
biotechs earnings
Zoetis Gears Up to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
ZTS' higher companion animal product sales are likely to have driven revenues in fourth-quarter 2024 in both the United States and International segments.
EXELNegative Net Change SRPTNegative Net Change ZTSPositive Net Change MIRMNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Gilead Sciences to Report Q4 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Investors' focus will likely be on GILD's HIV franchise performance and oncology sales when the company reports fourth-quarter 2024 results.
GILDNegative Net Change VRTXNegative Net Change EXELNegative Net Change SRPTNegative Net Change
biotechnology biotechs earnings pharmaceuticals
ADMA Loses 8.9% in a Month: How Should You Play the Stock?
by Ekta Bagri
ADMA Biologics' shares lose 8.9% in a month after putting up a phenomenal performance in the past 12 months. While the prospects remain sound, the exceptional rally witnessed by the stock might limit any further gain.
GRFSPositive Net Change ADMANegative Net Change TAKPositive Net Change
biotechnology biotechs medical pharmaceuticals
IMVT Q3 Loss Wider Than Expected, Stock Down, Pipeline in Focus
by Zacks Equity Research
Immunovant stock down on dismal third-quarter fiscal 2025 results. It is on track to initiate 10 studies on IMVT-1402 across various autoimmune indications.
ALNYPositive Net Change BMRNNegative Net Change CSTLPositive Net Change IMVTNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
DNLI Reports Upbeat Longer-Term Data From Hunter Syndrome Study
by Zacks Equity Research
Denali announces encouraging additional longer-term data from the phase I/II Hunter Syndrome study of its investigational therapy, tividenofusp alfa.
ALNYPositive Net Change BMRNNegative Net Change DNLINegative Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
Moderna Poised to Report Q4 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
When MRNA reports fourth-quarter earnings, investors will likely focus on pipeline updates.
MRKPositive Net Change MRNANegative Net Change SRPTNegative Net Change CRSPPositive Net Change
biotechs earnings medical messenger-rna pharmaceuticals vaccines
CRISPR Therapeutics Stock Before Q4 Earnings: To Buy or Not to Buy?
by Sundeep Ganoria
On CRSP's fourth-quarter 2024 earnings call, investors' focus will likely be on the sales figure of Casgevy, its first marketed product.
VRTXNegative Net Change BEAMPositive Net Change NTLANegative Net Change CRSPPositive Net Change
biotechs crispr earnings-preview medical
Insmed's NDA for Lung Disease Drug Gets FDA's Priority Review
by Zacks Equity Research
The FDA accepts and grants priority review to INSM's NDA for brensocatib to treat patients with non-cystic fibrosis bronchiectasis. A decision is due on Aug. 12, 2025.
INSMPositive Net Change ARGXPositive Net Change CSTLPositive Net Change HRMYNegative Net Change
biotechs
BMY Q4 Earnings and Sales Beat Estimates, Shares Down on 2025 Outlook
by Zacks Equity Research
BMY beats on both earnings and sales in the fourth quarter of 2024. However, shares are trading down as the guidance for 2025 is below expectations.
ALNYPositive Net Change BMYNegative Net Change PFENegative Net Change BMRNNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
AZN Q4 Earnings Lag, Sales Beat, Stock Up on China Probe Update
by Zacks Equity Research
AstraZeneca reports mixed results in the fourth quarter. It gains in pre-market after assuring investors that the business impact of the Chinese investigations remains minor.
SNYPositive Net Change AZNPositive Net Change MRKPositive Net Change AMGNPositive Net Change
biotechs earnings medical pharmaceuticals vaccines
Zacks Initiates Coverage of bioAffinity With Neutral Recommendation
by Debanjana Dey
Discover why Zacks rates bioAffinity as "Neutral", being the first on Wall Street to initiate coverage on the stock. Explore BIAF's promising growth prospects and financial health amid market challenges.
BIAFNegative Net Change
biotechnology biotechs medical